肺癌铂类化疗所致周围神经毒性与SNP相关性研究

目前肺癌发病率与死亡率均居恶性肿瘤首位,铂类药物已广泛应用于肺癌等多种癌症的治疗。然而,铂类药物化疗取得较佳疗效的同时,往往由于严重的毒副反应而限制了其使用剂量,从而难以达到最佳疗效。其中,铂类药物化疗所引起的周围神经毒性(peripheral neurotoxicity,PN)十分常见。与此同时,临床中周围神经毒性的发生存在较大的个体性差异,其药物代谢相关基因的单核苷酸多态性(single nucleotide polymorphism,SNP)的遗传变异可能是引起PN发生个体差异的重要原因之一。本文就DNA修复酶、药物代谢酶、转运体等相关基因的SNP与铂类化疗引起的PN之间的相关性作一综述。     

ERCC1 多态性与肺癌铂类化疗耐药的关系研究

目的:研究DNA切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)单核苷酸多态性与非小细胞肺癌铂类药物化疗敏感性的关系。方法:应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1 Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果:89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至少一个变异基因型(TC和TT基因型)患者的有效率分别为38.5%和61.5%(X2=2.151,p=0.142),基因型在化疗有效组和无效组之间的分布无差异(p>0.05)。结论:ERCC1Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。     

ERCC1多态性与肺癌铂类化疗耐药的关系研究

目的：研究DNA切除修复交叉互补基因1（excision repair cross-complementing gene1,ERCC1）单核苷酸多态性与非小细胞肺癌铂类药物化疗敏感性的关系。方法：应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1 Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果：89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至少一个变异基因型（TC和TT基因型）患者的有效率分别为38.5%和61.5%（X2=2.151,p=0.142）,基因型在化疗有效组和无效组之间的分布无差异（p〉0.05）。结论：ERCC1Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。     

TLR4基因rs10983755位点单核苷酸多态性与非小细胞肺癌易感性的相关性研究

目的:探讨TLR4基因rs10983755 A/G单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)易感性的相关性。方法:采用病例-对照研究方法纳入160例非小细胞肺癌患者(NSCLC组)和160例健康对照(NC组),利用MassARRAY飞行时间质谱生物芯片系统对TLR4基因rs10983755位点的单核苷酸多态性进行分型检测,并进行统计学分析。结果:rs10983755等位基因频率在中国汉族NSCLC患者和健康人群中的分布差异具有统计学意义(P0.05),A等位基因携带者NSCLC发生风险是G等位基因携带者的1.821倍(95%CI=1.124~2.906);rs10983755基因型频率在NSCLC患者和健康人群中分布差异具有统计学意义(P0.05),AA+AG基因型NSCLC发生风险是GG基因型的2.103倍(95%CI=1.118~3.898)。结论:TLR4基因rs10983755 A/G单核苷酸多态性与NSCLC的易感性显著相关,A是风险等位基因。     

药物相关转运蛋白基因多态性的研究进展

药物相关转运蛋白不但与肿瘤多药耐药现象密切相关,而且在人体内广泛参与药物的吸收、分布、代谢和排泄等过程。其编码基因的单核苷酸多态性(singlenucleotidepolymorphism,SNP)位点变异可能与药物转运蛋白的表达、转运功能密切相关,决定了临床常见的个体/群体药物反应差异性。本文主要介绍了近年来有关药物相关转运蛋白SNP位点基因多态性,以及与临床常见表型相关性的研究。     

SNPs及其在水产动物遗传学与育种学研究中的应用

1 SNP简介1.1 SNP的概念单核苷酸多态性(Single nucleotide polymorphism,SNP)指基因组DNA序列中某个特定位点的单个核苷酸发生变异而引起的序列多态性,包括单碱基的转换、颠换、插入及缺失等形式,其中一种等位基因在群体中的频     

微测序技术分析人类单核苷酸多态性

单核苷酸多态性 (singlenucleotidepolymorphism)是指染色体基因组水平上单个核苷酸变异引起的DNA序列多态性 ,即一种二等位基因标记。目前推断在基因组中至少有 30万个SNP[1 ] 。随着分子遗传学的发展 ,疾病研究从对单基因疾病的研究转向探讨多基因疾病 (如心血管疾病、神经系统疾病、各种肿瘤等 )的相关因素。因此 ,需要在人类基因组中找到一种数目众多、分布广泛且相对稳定的遗传标记 ,单核苷酸多态性正代表了这样一种标记。因此SNPs已成为继第一代限制性片段多态性标记 ,第二代微卫星多态性标记后具有重要研究价值的第三代基因遗传…     

自噬通路基因多态性与晚期非小细胞肺癌含铂化疗疗效的相关性分析

对晚期非小细胞肺癌患者采用含铂化疗是肺癌临床治疗中非常重要的方法,然而不同患者对含铂化疗的敏感性却存在着明显的个体差异,这提示发现潜在的分子标志物对预测临床中含铂化疗疗效具有关键作用。本研究旨在探索自噬通路基因多态性与晚期非小细胞肺癌含铂化疗疗效之间的相关性,以期寻找可能影响含铂化疗药物敏感性的分子标记。本研究纳入了1004例接受含铂化疗的晚期非小细胞肺癌患者,分析了自噬通路中13个基因上的99个SNP位点与含铂化疗临床获益、无疾病进展时间及总生存时间之间的相关性。研究发现,位于ULK1基因的位点rs7953348(G>A) (P=0.017, OR:0.67, 95%CI:0.49~0.93)和rs12303764(A>C) (P=0.009, OR:0.63, 95%CI:0.45-0.89)及位于ATG14基因上的位点rs17742719(C>A) (P=0.002, OR:1.83, 95%CI:1.26~2.66)、rs8003279(A>G) (P=0.006, OR:1.65, 95%CI:1.16~2.35)和rs1009647(G>A) (P=0.002, OR:1.70, 95%CI:1.22~2.37)与临床获益存在显著关联,位于DRAM基因上的位点rs7955890(G>A) (P=0.004, HR:0.63; 95%CI:0.46~0.86)和rs17032060(G>A) (P=0.006, HR:0.65, 95%CI:0.48~0.88)及位于ATG3基因上的位点rs13082005(G>A) (P=0.012, HR:1.27,95%CI:1.05~1.53)与含铂化疗的无疾病进展时间显著相关,位于ULK1基因的位点rs7953348(G>A) (P=0.011, HR:0.74, 95%CI:0.58~0.93)和位于ATG10基因上的位点rs1864183(G>A) (P=0.016, HR:0.42, 95%CI:0.21~0.85)对含铂化疗的总生存时间有着显著影响。研究结果提示自噬通路在含铂化疗敏感性中发挥着重要作用,自噬通路基因多态性可能是预测含铂化疗疗效的潜在分子标志物,这可能为临床上肺癌的个体化医疗提供一定的理论基础。     

单核苷酸多态性及其在水稻中的应用(综述)

单核苷酸多态性(single nucleotide polymorphism,SNP)主要是指基因组的DNA由于单个核苷酸的变异所引起的DNA序列多态性。本文介绍SNP的检测方法及其在水稻中的研究进展和应用。     

155例复发小细胞肺癌患者首诊临床特征分析

目的探讨小细胞肺癌(SCLC)一线含铂方案治疗后短期内疾病复发进展的相关临床因素。方法对2009年1月至2013年12月于大连医科大学附属第二医院接受一线含铂方案治疗的SCLC病例进行回顾性分析,根据疾病复发进展时间将病例分为难治复发组和敏感复发组,分析比较两组病例首诊临床特征。结果相比敏感复发组病例,难治复发组病例更多见于首诊时广泛期、肝转移、骨转移、LDH(乳酸脱氢酶)300U/L、NSE(神经元特异性烯醇化酶)65.2ng/mL、CYFRA21-1(细胞角蛋白19片段)9.9ng/mL的患者。Logistic多因素相关性分析显示,广泛期是SCLC一线含铂方案治疗后短期内疾病复发进展的独立影响因素(OR=4.1,[95%CI:1.731-9.740],P=0.001)。结论广泛期是SCLC一线含铂方案治疗后短期内疾病复发进展的独立影响因素,首诊广泛期的SCLC患者,要注意一线含铂方案治疗后疾病短期内复发进展可能。     

XPD和ECC1 基因多态性与进展期结直肠癌患者铂剂为基础化疗方案 治疗的毒副作用 *

目的:探讨着色性干皮病基因D(Xeroderma Pigmentosum D,XPD)和剪切修复交叉互补基因l(Excision Repair Cross Complementing Gene 1,ERCCl)多态性基因型与以铂类为基础的化疗方案治疗结直肠癌的毒副作用的关系。方法:采用聚合酶链反应--限制性片段长度多态性(Polymerase Chain Reaction-Restriction Fragment Length Polymorphism,PCR-RFLP)分析方法,对我院2010年12月至2013年12月应用含奥沙利铂方案治疗的42例汉族进展期结直肠癌患者的XPD和XRCCl的多态性基因型进行分析,比较不同基因型与临床病理因素及化疗不良反应的关系。结果:XPD、ERCC1的单核苷酸多态性(Single Nucleotide Polymorphism,SNP)分布与年龄、性别、淋巴转移、肿瘤的部位、化疗史、分化程度、器官转移个数差异无统计学意义(P>0.05);XPD基因型中,其中AA基因型以骨髓抑制、恶心呕吐为主,AG基因型以腹泻及肝肾损伤为主,GG基因型以神经毒性及口腔黏膜炎为主,差异有统计学意义(P<0.05);ERCC1基因型中,LG基因型以骨髓抑制、恶心呕吐及腹泻等症状为主,LL基因型以肝肾损伤、神经毒性及口腔黏膜炎为主,差异有统计学意义(P<0.05)。结论:XPD和ERCCl的基因型可能与结直肠癌铂类药物化疗的不良反应有关。     

Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells

Background

Gemcitabine is used as a standard drug treatment for non-small cell lung cancer (NSCLC), but treatment responses vary among patients. Our previous studies demonstrated that POLA2 + 1747 GG/GA single nucleotide polymorphism (SNP) improves differential survivability and mortality in NSCLC patients. Here, we determined the association between POLA2 and gemcitabine treatment in human lung cancer cells.

Results

Human PC9, H1299 and H1650 lung cancer cell lines were treated with 0.01-100 μM gemcitabine for 72 h. Although all 3 cell lines showed decreased cell viability upon gemcitabine treatment, H1299 was found to be the most sensitive to gemcitabine treatment. Next, sequencing was performed to determine if POLA2 + 1747 SNP might be involved in gemcitabine sensitivity. Data revealed that all 3 cell lines harbored the wild-type POLA2 + 1747 GG SNP, indicating that the POLA2 + 1747 SNP might not be responsible for gemcitabine sensitivity in the cell lines studied. Silencing of POLA2 gene in H1299 was then carried out by siRNA transfection, followed by gemcitabine treatment to determine the effect of POLA2 knockdown on chemosensitivity to gemcitabine. Results showed that H1299 exhibited increased resistance to gemcitabine after POLA2 knockdown, suggesting that POLA2 does not act alone and may cooperate with other interacting partners to cause gemcitabine resistance.

Conclusions

Collectively, our findings showed that knockdown of POLA2 increases gemcitabine resistance in human lung cancer cells. We propose that POLA2 may play a role in gemcitabine sensitivity and can be used as a prognostic biomarker of patient outcome in NSCLC pathogenesis.

     

Association of the FAM46A Gene VNTRs and BAG6 rs3117582 SNP with Non Small Cell Lung Cancer (NSCLC) in Croatian and Norwegian Populations

We analyzed for associations between a variable number of tandem repeat (VNTR) polymorphism in the Family with sequence similarity 46, member A (FAM46A) gene and a single nucleotide polymorphism (rs3117582) in the BCL2-Associated Athanogene 6 (BAG6) with non small cell lung cancer in Croatian and Norwegian subjects. A total of 503 (262 Croatian and 241Norwegian) non small cell lung cancer patients and 897 controls (568 Croatian and 329 Norwegian) were analyzed. We found that the frequency of allele b (three VNTR repeats) of FAM46A gene was significantly increased in the patients compared to the healthy controls in the Croatian and the combined Croatian and Norwegian subjects. Genotype frequencies of cd (four and five VNTR repeats) and cc (four VNTR repeats homozygote) of the FAM46A gene were significantly decreased in the patients compared to the healthy controls in the Croatian and Norwegian subjects, respectively. Logistic regression analyses revealed FAM46A genotype cc to be an independent predictive factor for non small cell lung cancer risk in the Norwegian subjects after adjustment for age, gender and smoking status. This is the first study to suggest an association between the FAM46A gene VNTR polymorphisms and non small cell lung cancer. We found also that BAG6 rs3117582 SNP was associated with non small cell lung cancer in the Norwegian subjects and the combined Croatian-Norwegian subjects corroborating the earlier finding that BAG6 rs3117582 SNP was associated with lung cancer in Europeans. Logistic regression analyses revealed that genotypes and alleles of BAG6 were independent predictive factor for non small cell lung cancer risk in the Norwegian and combined Croatian-Norwegian subjects, after adjustment for age and gender.     

Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer

Primary chemotherapy is a useful strategy for the treatment of locally advanced breast cancer and therefore allows in vivo evaluation of the action of cytotoxic drugs and the possibility of accomplishing conservative breast surgeries, as well as the early treatment of metastasis. Mechanisms of resistance to the drugs include the action of protein associated with the efflux of drugs from the intracellular environment hindering their activity; one of the most studied proteins is P-glycoprotein codified by the MDR-1 gene. The presence of polymorphisms can determine different physiological actions of these proteins, intervening with the response of the drug's action. We evaluated the presence of single nucleotide polymorphism (SNP) C3435T of the MDR-1 gene and its correlation with the response to primary chemotherapy using the RECIST criteria. Forty-one Brazilian women with stages II and III breast cancer using the PCR-RFLP analysis were evaluated. Thirty-three patients with the SNP genotype (TT and CT) and eight patients with the wild genotype (CC) were found; there was no statistically significant correlation between the diverse genotypes and the clinical and pathological responses according to the Cramer correlation coefficient (V = 0.14). The parameters: nuclear and histological degree, and estrogens, progesterone and c-erb B2 receptors did not demonstrate a statistical correlation with the SNP C3435T. Patients with complete pathological response (12.5%) showed only the polymorphic genotype and not the wild genotype. The characteristics of miscegenation in our population could explain the absence of the characterization of a sub-group of individuals where the presence of the polymorphic genotype influenced the response to the primary chemotherapy.     

Proliferating activity, DNA ploidy changes of lung cancer cells before and after chemotherapy

To assess proliferating activity, DNA ploidy changes of lung cancer cells before and after chemotherapy, we performed a flow cytometry analysis (FC) using fresh bronchoscopy specimens from 38 patients with lung cancer. Among 33 males and 5 females, squamous cell carcinoma (NSLC) was recognized in 12 males, 15 males had small cell lung cancer (SCLC) and 6 males had lung cancer with no histological type (LC) defined. Three women had SCLC, 1 had NSCLC and one had LC. Control consisted of 11 COPD patients. The percentage of diploid cells was significantly lower and cells with hypoploid cells were significantly higher in study group before treatment. High percentage of G2M cells characterised NSCLC and LC groups, whether high number of S phase cells characterised NSCLC and SCLC group before treatment. The treatment lowered percentage of G2M cells in NSCLC and CA group, whether diploid, hypoploid and S phase cells did not differ than those from before treatment.     

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.

Resistance to chemotherapy is a principal problem in the treatment of small cell lung cancer (SCLC). We show here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites. Adhesion of SCLC cells to ECM enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of beta1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis. SCLC may create a specialized microenvironment, and the survival of cells bound to ECM could explain the partial responses and local recurrence of SCLC often seen clinically after chemotherapy. Strategies based on blocking beta1 integrin-mediated survival signals may represent a new therapeutic approach to improve the response to chemotherapy in SCLC.     

A Regulatory MDM4 Genetic Variant Locating in the Binding Sequence of Multiple MicroRNAs Contributes to Susceptibility of Small Cell Lung Cancer

A functional rs4245739 A>C single nucleotide polymorphism (SNP) locating in the MDM43’-untranslated (3’-UTR) region creates a miR-191-5p or miR-887-3p targeting sites. This change results in decreased expression of oncogene MDM4. Therefore, we examined the association between this SNP and small cell lung cancer (SCLC) risk as well as its regulatory function in SCLC cells. Genotypes were determined in two independent case-control sets consisted of 520SCLC cases and 1040 controls from two regions of China. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression. The impact of the rs4245739 SNP on miR-191-5p/miR-887-3p mediated MDM4 expression regulation was investigated using luciferase reporter gene assays. We found that the MDM4 rs4245739AC and CC genotypes were significantly associated with decreased SCLC susceptibility compared with the AA genotype in both case-control sets (Shandong set: OR = 0.53, 95% CI = 0.32–0.89, P = 0.014; Jiangsu set: OR = 0.47, 95% CI = 0.26–0.879, P = 0.017). Stratified analyses indicated that there was a significantly multiplicative interaction between rs4245739 and smoking (P _interactioin = 0.048). After co-tranfection of miRNAs and different allelic-MDM4 reporter constructs into SCLC cells, we found that the both miR-191-5p and miR-887-3p can lead to significantly decreased MDM4 expression activities in the construct with C-allelic 3’-UTR but not A-allelic 3’-UTR, suggesting a consistent genotype-phenotype correlation. Our data illuminate that the MDM4rs4245739SNP contributes to SCLC risk and support the notion that gene 3’-UTR genetic variants, impacting miRNA-binding, might modify SCLC susceptibility.     

Small cell lung cancer,an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1

Small cell lung cancer (SCLC) is one of the most malignant neoplasms in common human cancers. The tumor is composed of small immature-looking cells with a round or fusiform shape, which possesses weak adhesion features among them, suggesting that SCLC shows the morphological characteristics of epithelial to mesenchymal transition (EMT). SCLC is characterized by high metastatic and recurrent rates, sensitivity to the initial chemotherapy, and easy acquirement of chemoresistance afterwards. These characters may be related to the EMT phenotype of SCLC. Notch signaling is an important signaling pathway, and could have roles in regulating neuroendocrine differentiation, proliferation, cell adhesion, EMT, and chemoresistance. Notch1 is usually absent in SCLC in vivo, but could appear after chemotherapy. Notch1 can enhance cell adhesion by induction of E-cadherin in SCLC, which indicates mesenchymal to epithelial transition. On the other hand, achaete-scute complex homologue 1 (ASCL1), negatively regulated by Notch signaling, is a lineage-specific gene of SCLC, and functions to promote neuroendocrine differentiation as well as EMT. ASCL1-transfected adenocarcinoma cell lines induced neuroendocrine phenotypes and lost epithelial cell features. SCLC is characterized by neuroendocrine differentiation and EMT-like features, which could be produced by inactive Notch signaling and ASCL1 expression. In addition, chemical and radiation treatments can activate Notch signaling, which suppress neuroendocrine differentiation and induces chemoradioresistance, accompanied by secession from EMT. Thus, the status of Notch signaling and ASCL1 expression may determine the cell behaviors of SCLC partly through modifying EMT phenotypes.